腎臓がん治療薬市場- 世界の産業規模、シェア、動向、機会、予測、治療クラス別、薬理学クラス別、地域別、競合別、2020-2030F

腎臓がん治療薬の世界市場は、2024年に71億5,000万米ドルと評価され、2030年までのCAGRは6.45%で、予測期間中に力強い成長が予測されています。

腎臓がんは、腎細胞がんとしても知られ、血液中の老廃物や余分な水分をろ過して尿を形成する役割を担う豆のような形をした臓器である腎臓に発生するがんの一種です。腎臓がんは、医学的には腎細胞がん（RCC）と呼ばれ、効果的な治療戦略を必要とする複雑で困難な疾患です。医学研究の進歩と医薬品の技術革新が加速する中、いくつかの主要促進要因が腎臓がん治療薬市場の成長と進化を後押ししています。標的療法は、がん細胞の増殖と生存に不可欠な特定の分子や経路を阻害するように設計された薬剤クラス別です。腎臓がんでは、標的治療薬が治療に革命をもたらしました。例えば、スニチニブ、パゾパニブ、アキシチニブなどのチロシンキナーゼ阻害剤（TKI）です。これらの薬剤は、腫瘍の成長と血管新生（新しい血管の形成）を促進するシグナル伝達経路を破壊します。これらの薬剤の導入により、腎臓がん治療の状況は劇的に変化しました。かつては限られた選択肢しかなかった患者も、今では生存率の改善と生活の質の向上をもたらすさまざまな治療法を利用できるようになりました。調査が進むにつれ、腎臓がん治療薬市場はさらなる進歩を遂げようとしています。併用療法、個別化医療アプローチ、新規ターゲットの統合が視野に入っています。さらに、研究者、製薬企業、ヘルスケア団体、患者支援団体間の継続的な協力関係は、革新的な治療法の開発を形成し続け、最終的には腎臓がんに直面している患者の転帰改善につながるであろう。

市場促進要因

腎臓がん罹患率の上昇

主な市場課題

耐性と治療の不均一性

主要市場動向

個別化医療革命

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の腎臓がん治療薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 治療クラス別（標的療法、免疫療法、化学療法）
  • 薬理学的クラス別（血管新生阻害剤、モノクローナル抗体、mTOR阻害剤、サイトカイン免疫療法（IL-2））
  • 企業別（2024）
  • 地域別
• 市場マップ

第6章 北米の腎臓がん治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州の腎臓がん治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域の腎臓がん治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米の腎臓がん治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの腎臓がん治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 PESTEL分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• Novartis AG
• Pfizer Inc.
• Bayer AG
• Genentech Inc.
• Bristol-Myers Squibb
• Eisai Co., Ltd.
• Exelixis Inc
• Prometheus Laboratories Inc
• Glaxosmithkline PLC.
• F. Hoffmann-LA Roche AG

第16章 戦略的提言

第17章 調査会社について・免責事項

Global Kidney Cancer Drugs Market was valued at USD 7.15 Billion in 2024 and is anticipated to project robust growth in the forecast period with a CAGR of 6.45% through 2030. Kidney cancer, also known as renal cell carcinoma, is a type of cancer that originates in the kidneys, the bean-shaped organs responsible for filtering waste and excess fluids from the blood to form urine. Kidney cancer, medically termed renal cell carcinoma (RCC), is a complex and challenging disease that demands effective treatment strategies. As medical research advances and pharmaceutical innovation accelerates, several key drivers are propelling the growth and evolution of the kidney cancer drugs market. Targeted therapies are a class of drugs designed to inhibit specific molecules or pathways that are crucial for cancer cell growth and survival. In kidney cancer, targeted therapies have revolutionized treatment. Examples include tyrosine kinase inhibitors (TKIs) such as sunitinib, pazopanib, and axitinib. These drugs disrupt the signaling pathways that promote tumor growth and angiogenesis (formation of new blood vessels). The landscape of kidney cancer treatment has been dramatically transformed by the introduction of these drugs. Patients who once faced limited options now have access to a range of therapies that offer improved survival rates and enhanced quality of life. As research continues, the kidney cancer drugs market is poised for further advancements. Combination therapies, personalized medicine approaches, and the integration of novel targets are on the horizon. Additionally, the ongoing collaboration among researchers, pharmaceutical companies, healthcare organizations, and patient advocacy groups will continue to shape the development of innovative therapies and ultimately lead to better outcomes for patients facing kidney cancer.

Key Market Drivers

Rising Incidence of Kidney Cancer

The global kidney cancer market is experiencing significant expansion, largely driven by the rising incidence of kidney cancer worldwide. In 2022, kidney cancer accounted for 434,840 newly diagnosed cases globally, making it the 14th most prevalent cancer worldwide. It ranked as the 10th most diagnosed cancer among men and the 13th among women, underscoring its significant impact on global healthcare systems and oncology markets. The increasing number of renal cell carcinoma (RCC) cases-the most common type of kidney cancer-has created a growing demand for advanced diagnostics, innovative therapeutics, and improved healthcare infrastructure. This trend is not only shaping market dynamics but also influencing the strategic direction of pharmaceutical companies, healthcare providers, and investors. The global population is aging at an unprecedented rate. Between 1974 and 2024, the proportion of individuals aged 65 and older nearly doubled, rising from 5.5% to 10.3%, and age is a significant risk factor for kidney cancer. With higher life expectancy, the number of kidney cancer cases is expected to increase, driving demand for effective treatment options. Developed regions such as North America and Europe report higher incidence rates due to advanced screening programs and improved diagnostic capabilities. Meanwhile, emerging economies in Asia-Pacific are seeing rising cases due to lifestyle changes and increasing industrialization, leading to a higher demand for cancer therapeutics.

Key Market Challenges

Resistance and Treatment Heterogeneity

Despite the advancements in targeted therapies and immunotherapies, the development of resistance to these treatments remains a significant challenge in kidney cancer. Over time, tumors can evolve and adapt, rendering once-effective therapies ineffective. This challenge underscores the need for continuous research to understand the mechanisms of resistance and develop strategies to overcome it. Additionally, kidney cancer is not a homogeneous disease. Different subtypes and genetic variations contribute to variations in treatment response. Developing therapies that are effective across diverse patient populations is a complex endeavor that requires a deep understanding of tumor biology and personalized medicine approaches.

Key Market Trends

Personalized Medicine Revolution

The era of personalized medicine has dawned upon the field of kidney cancer treatment, offering immense promise for improved patient outcomes. With the advent of precision oncology, the one-size-fits-all approach to treatment is giving way to tailored interventions that account for individual genetic profiles and biomarker expression. Advancements in genomics and molecular diagnostics enable oncologists to identify specific genetic mutations or alterations driving a patient's kidney cancer. Armed with this information, they can prescribe targeted therapies that are more likely to elicit a favorable response. This shift towards personalized treatment approaches not only enhances the efficacy of drugs but also minimizes the potential for adverse effects.

Key Market Players

• Novartis AG
• Pfizer Inc.
• Bayer AG
• Genentech Inc.
• Bristol-Myers Squibb
• Eisai Co., Ltd.
• Exelixis Inc
• Prometheus Laboratories Inc
• Glaxosmithkline PLC.
• F. Hoffmann-LA Roche AG

Report Scope:

In this report, the Global Kidney Cancer Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Kidney Cancer Drugs Market, By Therapeutic Class:

• Targeted Therapy
• Immunotherapy
• Chemotherapy

Kidney Cancer Drugs Market, By Pharmacologic Class:

• Angiogenesis Inhibitors
• Monoclonal Antibodies
• mTOR Inhibitors
• Cytokine Immunotherapy (IL-2)

Kidney Cancer Drugs Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Kidney Cancer Drugs Market.

Available Customizations:

Global Kidney Cancer Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Kidney Cancer Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapeutic Class (Targeted Therapy, Immunotherapy, Chemotherapy)
  • 5.2.2. By Pharmacologic Class (Angiogenesis Inhibitors, Monoclonal Antibodies, mTOR Inhibitors, Cytokine Immunotherapy (IL-2))
  • 5.2.3. By Company (2024)
  • 5.2.4. By Region
• 5.3. Market Map

6. North America Kidney Cancer Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapeutic Class
  • 6.2.2. By Pharmacologic Class
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Kidney Cancer Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapeutic Class
      • 6.3.1.2.2. By Pharmacologic Class
  • 6.3.2. Mexico Kidney Cancer Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapeutic Class
      • 6.3.2.2.2. By Pharmacologic Class
  • 6.3.3. Canada Kidney Cancer Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapeutic Class
      • 6.3.3.2.2. By Pharmacologic Class

7. Europe Kidney Cancer Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value & Volume
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapeutic Class
  • 7.2.2. By Pharmacologic Class
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Kidney Cancer Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapeutic Class
      • 7.3.1.2.2. By Pharmacologic Class
  • 7.3.2. Germany Kidney Cancer Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapeutic Class
      • 7.3.2.2.2. By Pharmacologic Class
  • 7.3.3. United Kingdom Kidney Cancer Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapeutic Class
      • 7.3.3.2.2. By Pharmacologic Class
  • 7.3.4. Italy Kidney Cancer Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapeutic Class
      • 7.3.4.2.2. By Pharmacologic Class
  • 7.3.5. Spain Kidney Cancer Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapeutic Class
      • 7.3.5.2.2. By Pharmacologic Class

8. Asia-Pacific Kidney Cancer Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value & Volume
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapeutic Class
  • 8.2.2. By Pharmacologic Class
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Kidney Cancer Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapeutic Class
      • 8.3.1.2.2. By Pharmacologic Class
  • 8.3.2. India Kidney Cancer Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapeutic Class
      • 8.3.2.2.2. By Pharmacologic Class
  • 8.3.3. South Korea Kidney Cancer Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapeutic Class
      • 8.3.3.2.2. By Pharmacologic Class
  • 8.3.4. Japan Kidney Cancer Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapeutic Class
      • 8.3.4.2.2. By Pharmacologic Class
  • 8.3.5. Australia Kidney Cancer Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapeutic Class
      • 8.3.5.2.2. By Pharmacologic Class

9. South America Kidney Cancer Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapeutic Class
  • 9.2.2. By Pharmacologic Class
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Kidney Cancer Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapeutic Class
      • 9.3.1.2.2. By Pharmacologic Class
  • 9.3.2. Argentina Kidney Cancer Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapeutic Class
      • 9.3.2.2.2. By Pharmacologic Class
  • 9.3.3. Colombia Kidney Cancer Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapeutic Class
      • 9.3.3.2.2. By Pharmacologic Class

10. Middle East and Africa Kidney Cancer Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapeutic Class
  • 10.2.2. By Pharmacologic Class
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Kidney Cancer Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapeutic Class
      • 10.3.1.2.2. By Pharmacologic Class
  • 10.3.2. Saudi Arabia Kidney Cancer Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapeutic Class
      • 10.3.2.2.2. By Pharmacologic Class
  • 10.3.3. UAE Kidney Cancer Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapeutic Class
      • 10.3.3.2.2. By Pharmacologic Class

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Novartis AG
  • 15.1.1. Business Overview
  • 15.1.2. Product & Service Offerings
  • 15.1.3. Recent Developments
  • 15.1.4. Financials (If Listed)
  • 15.1.5. Key Personnel
  • 15.1.6. SWOT Analysis
• 15.2. Pfizer Inc.
• 15.3. Bayer AG
• 15.4. Genentech Inc.
• 15.5. Bristol-Myers Squibb
• 15.6. Eisai Co., Ltd.
• 15.7. Exelixis Inc
• 15.8. Prometheus Laboratories Inc
• 15.9. Glaxosmithkline PLC.
• 15.10. F. Hoffmann-LA Roche AG

16. Strategic Recommendations

17. About Us & Disclaimer